Innovations at Geistlich Pharma AG – sustainable and responsible

Geistlich has been doing pioneering work in the development of biomaterials. The pioneering spirit of Geistlich runs through the company’s history and is essential for the company’s future: “Either you are a pioneer, or you stand still…” Geistlich's policy is not about commercialising innovations as quickly as possible. Geistlich develops in a sustainable and responsible manner.

Geistlich’s innovations have been breaking new grounds:

  • Geistlich Bio-Oss® has revolutionised dental bone regeneration and 
  • Geistlich Bio-Gide® has simplified Guided Bone Regeneration decisively.
  • Chondro-Gide® has opened new ways in cartilage regeneration.

The quality, safety and efficacy of the product are always of paramount importance. Geistlich has invested a lot: in new technologies, technical equipment and in the continuous initial and further training of its employees – and will continue to do so in the future.


The goal of Geistlich is to help patients obtain a better quality of life. This is done firstly with new products and secondly through the development of new technologies or new areas of application for products that are already available. The company’s innovation activities are organised accordingly. Eighty per cent of the innovation projects serve to develop products tailored to the customer’s requirements. The company uses the remaining 20 per cent to conduct basic research and to develop new possibilities for our already existing core competences (e.g. collagen expertise).

“Either you are a pioneer, or you stand still …“
Dr. Terance Hart, CSO Geistlich Pharma


Collaboration with experts

Geistlich Pharma AG employs highly specialised scientists in-house who have an excellent reputation in expert circles. There is also an intensive exchange with a large scientific network of international universities. Before introducing its products to the market, Geistlich Pharma AG evaluates them in detail together with experienced users and provides the scientific proof that they meet the high Geistlich requirements with regard to quality and efficacy. 


Dr. Mirjam Kessler
Director Corporate Communications